Science & Innovation

NAV® Technology Platform

REGENXBIO’s gene therapy product candidates deliver genes to cells using adeno-associated virus (AAV) vectors, which are nonreplicating viral delivery vehicles that are not known to cause disease.

Our product candidates all utilize viral vectors from our proprietary gene delivery platform, which we call our NAV Technology Platform.


The foundation of our NAV Technology Platform was discovered in an effort to identify next generation AAV vectors that could overcome the limitations of earlier generation AAV vectors (AAV1 through AAV6). We believe the key benefits of NAV Vectors include:

differentiator backdrop
Broad
Broad application across multiple disease states
differentiator backdrop
Delivery
Delivery of multiple types of genetic material
differentiator backdrop
Simplified
Simplified manufacturing relative to earlier generation AAV vectors
differentiator backdrop
Less
Less likely to trigger an immune response than earlier generation AAV vectors
differentiator backdrop
Improved
Improved gene expression over earlier generation AAV vectors, enabling longer-lasting treatment in a smaller dose
differentiator backdrop
Derived
Derived from natural sources with modifications to enable therapeutic use

We believe NAV Technology, which underpins our internal development programs and the programs of our licensees, will enable us and our partners to develop best-in-class gene therapy candidates for a wide range of therapeutic areas.